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Small molecule inhibitors reveal an indispensable
scaffolding role of RIPK2 in NOD2 signaling
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Abstract
RIPK2 mediates inflammatory signaling by the bacteria-sensing
receptors NOD1 and NOD2. Kinase inhibitors targeting RIPK2 are a
proposed strategy to ameliorate NOD-mediated pathologies. Here,
we reveal that RIPK2 kinase activity is dispensable for NOD2
inflammatory signaling and show that RIPK2 inhibitors function
instead by antagonizing XIAP-binding and XIAP-mediated ubiquiti-
nation of RIPK2. We map the XIAP binding site on RIPK2 to the loop
between b2 and b3 of the N-lobe of the kinase, which is in close
proximity to the ATP-binding pocket. Through characterization of a
new series of ATP pocket-binding RIPK2 inhibitors, we identify the
molecular features that determine their inhibition of both the
RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling.
Our study exemplifies how targeting of the ATP-binding pocket in
RIPK2 can be exploited to interfere with the RIPK2-XIAP interaction
for modulation of NOD signaling.
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Introduction
Receptor-interacting kinases (RIPKs) are components of innate
immune receptor signaling complexes where they become ubiquiti-
nated and contribute to NF-jB-mediated inflammatory signaling and
cell death (Hrdinka & Gyrd-Hansen, 2017; Annibaldi & Meier, 2018).
The intracellular bacteria-sensing receptors NOD1 and NOD2 (nu-
cleotide-oligomerization domain-containing proteins 1 and 2) stimu-
late inflammatory signaling by promoting RIPK2 ubiquitination in
response to binding of iE-DAP (D-glutamyl-meso-diaminopimelic
acid) and MDP (muramyl dipeptide) constituents of bacterial pepti-
doglycan, respectively (Girardin et al, 2003). NOD1/2 signaling
contributes to gastro-intestinal immunity (Philpott et al, 2014), and
genetic variants in NOD2 are the strongest susceptibility factors to
Crohn’s disease—one of the two major inflammatory bowel diseases
afflicting millions in Europe and North America alone (Hugot et al,
2001; Ogura et al, 2001; Ananthakrishnan, 2015). Mutations of
NOD2 have also been implicated in other auto-inflammatory granu-
lomatous pathologies such as Blau’s syndrome and early-onset
sarcoidosis (Caso et al, 2015).
Stimulation of NOD2 recruits RIPK2 along with several ubiquitin
(Ub) ligases, including IAP (Inhibitor of Apoptosis) proteins and
LUBAC (linear ubiquitin chain assembly complex) (Hasegawa et al,
2008; Bertrand et al, 2009; Tao et al, 2009; Damgaard et al, 2012;
Yang et al, 2013; Watanabe et al, 2014). These ligases, together
with deubiquitinases, coordinate the conjugation of Lys63- and
Met1-linked Ub chains (Lys63-Ub and Met1-Ub) on RIPK2 to facili-
tate signal transduction (Hitotsumatsu et al, 2008; Fiil et al, 2013;
Draber et al, 2015; Hrdinka et al, 2016). Lys63-Ub and Met1-Ub are
central for productive innate immune signaling and transcription of
nuclear factor-jB (NF-jB) target genes (Hrdinka & Gyrd-Hansen,
2017). Lys63-Ub is recognized by the TAK1-TAB 2/3 (TGFb-
activated kinase 1; TAK1-binding protein 2/3) kinase complex, and
Met1-Ub is bound by the IKK (IjB kinase) complex through the
subunit NEMO (NF-jB essential modifier; also known as IKKc). In
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turn, the kinase complexes are activated, leading to phosphoryla-
tion, ubiquitination, and degradation of the NF-jB inhibitory factor
IjBa and activation of MAP kinases (Hrdinka & Gyrd-Hansen,
2017).
XIAP (X-linked IAP) is indispensable for NOD2 signaling and
familial mutations in XIAP that impact on its function cause severe
immunodeficiency with variable clinical presentation, including
early-onset chronic colitis in ~20% of afflicted individuals (Bauler
et al, 2008; Krieg et al, 2009; Damgaard et al, 2012, 2013;
Speckmann et al, 2013; Pedersen et al, 2014). The ubiquitination of
RIPK2 by XIAP facilitates recruitment of LUBAC (Damgaard et al,
2012), which in turn conjugates Met1-Ub on RIPK2 (Fiil et al, 2013).
Previous data using small molecule inhibitors suggested that
catalytic activity of RIPK2 may contribute to XIAP-mediated RIPK2
ubiquitination (Canning et al, 2015; Nachbur et al, 2015). Conse-
quently, the activity of RIPK2 has been implicated in a subset of
systemic granulomatous inflammatory diseases (Jun et al, 2013)
and, in particular, ablation of Ripk2 or inhibition of RIPK2 by small-
molecule kinase inhibitors showed benefits in mouse models of
multiple sclerosis (Shaw et al, 2011; Nachbur et al, 2015) and
Crohn’s disease-like ileitis (Tigno-Aranjuez et al, 2014), positioning
RIPK2 as a new target against human inflammatory diseases.
However, the molecular basis for the cross-talk between the kinase
activity of RIPK2 and its role as a critical ubiquitinated scaffold
downstream of NOD1/2 remains enigmatic.
Here, we reveal that RIPK2 kinase activity is dispensable for
NOD2 inflammatory signaling, show that RIPK2 inhibitors function
instead by antagonizing XIAP-binding and XIAP-mediated ubiquiti-
nation of RIPK2, and identify structural features of RIPK2 required
for XIAP binding and for the design of efficient small molecule inhi-
bitors of NOD1/2-RIPK2-dependent signaling. Our study exemplifies
how targeting the ATP-binding pocket in RIPK2 can be exploited to
interfere with the RIPK2-XIAP interaction for modulation of NOD
signaling.
Results
RIPK2 kinase activity is dispensable for NOD2 signaling
Previous reports showed that tyrosine-kinase inhibitors such as
ponatinib, gefitinib, and the RIPK2-selective kinase inhibitors
GSK583 and WEHI-345 inhibit cellular responses to the NOD2
agonist MDP (or L18-MDP) by antagonizing RIPK2 function (Tigno-
Aranjuez et al, 2010; Canning et al, 2015; Nachbur et al, 2015;
Haile et al, 2016). In concordance, ponatinib and GSK583 inhibited
the degradation of IjBa and NF-jB-mediated production of the
chemokine CXCL8 in a dose-dependent manner in U2OS/NOD2 cells
stimulated with L18-MDP (Fig 1A–C). Of note, the U2OS/NOD2 cells
used in this study express doxycycline (DOX)-inducible HA-NOD2
and respond to L18-MDP without addition of DOX due to leakiness
of the promoter (Fiil et al, 2013). Small molecule kinase inhibitors
are categorized into multiple classes, depending on their mode of
binding (Roskoski, 2016). This includes type I inhibitors that inter-
act exclusively within the ATP-binding pocket, type II inhibitors that
bind both to the ATP, and an additional back pocket created when
the activation segment of a kinase adopts an inactive conformation,
and type III molecules that bind exclusively to this allosteric back
pocket. Curiously, we observed that a subset of known RIPK2 inhi-
bitors belonging to different classes displayed potent (nanomolar)
cellular activities, including ponatinib (a type II inhibitor) and
GSK583 (an ATP-competitive type I inhibitor), and that these mole-
cules also antagonized NOD2-mediated ubiquitination of RIPK2
(Figs 1C and EV1A; Canning et al, 2015). This implied that the
kinase activity of RIPK2 is required for its ubiquitination and, thus,
for NOD2 responses. To directly investigate this, we first ablated
RIPK2 (RIPK2 KO) by CRISPR-mediated gene editing in U2OS/NOD2
cells (Fig EV1B and C). As expected, degradation of IjBa and
production of CXCL8 in response to L18-MDP were completely
inhibited in RIPK2 KO cells (Park et al, 2007; Fig 1D and E). Rein-
troduction of wild-type (WT) RIPK2 restored RIPK2 ubiquitination
and CXCL8 production, and partially restored IjBa degradation,
confirming that the signaling defect was due to the absence of RIPK2
(Fig 1D and E). Next, RIPK2 KO cells were reconstituted with
kinase-dead human RIPK2 variants in which the ATP-binding lysine
47 was substituted for arginine (K47R) or the catalytic aspartate 146
in the “HRD” motif (HHD in human RIPK2) was substituted for
asparagine (D146N) (Pellegrini et al, 2017; Figs 1F and G, and
EV1D). Strikingly, introduction of both kinase-dead RIPK2 mutants
restored NOD2 signaling and CXCL8 production to a similar level
as with WT RIPK2 in two independent RIPK2 KO clones, showing
that the catalytic function is not needed for RIPK2’s role in NOD2-
dependent inflammatory signaling (Figs 1G and H, and EV1E).
RIPK2 ubiquitination in response to L18-MDP was also not
affected by the K47R and D146N mutations, which is surprising
since kinase inhibitors blocked RIPK2 ubiquitination (Figs 1C and
2A). Moreover, ponatinib prevented ubiquitination of the kinase-
dead RIPK2 variants after NOD2 stimulation and antagonized their
capacity to induce NF-jB activation (Fig 2A and B), suggesting that
the inhibition of RIPK2 ubiquitination and NOD2 signaling by pona-
tinib is independent of its inhibition of RIPK2 kinase activity.
Although RIPK2 is a high-affinity cellular target of ponatinib, the
molecule is a promiscuous kinase inhibitor (Fauster et al, 2015;
Najjar et al, 2015; Appendix Fig S1A; Dataset EV1). To determine
whether ponatinib’s inhibitory activity was a result of its binding to
RIPK2, we substituted the threonine 95 “gatekeeper” residue with a
bulky tryptophan (T95W) to prevent ponatinib’s binding to the
RIPK2 ATP-binding pocket (Fig 2C). We first confirmed that the
T95W mutation indeed ablated the binding of ponatinib to RIPK2 in
cells at the concentrations used to inhibit signaling using a nano-
bioluminescence resonance energy transfer (nanoBRET) assay
(Vasta et al, 2018) and cellular thermal shift assay (CETSA; Jafari
et al, 2014), which measure cellular target engagement. Use of our
recently reported ponatinib-derived kinase tracer SGC-590001 (Vasta
et al, 2018) in conjunction with nanoLuc-RIPK2 showed that the
T95W mutation prevented detectable interaction at inhibitor
concentrations up to more than 100 nM (Fig 2D). In accordance
with this and with previous findings (Canning et al, 2015), pona-
tinib (300 nM) induced a substantial thermal shift indicative of
binding to WT RIPK2 (and K47R RIPK2), but this was not observed
for the RIPK2 T95W and K47R+T95W mutants (Appendix Fig S1B).
Introduction of the T95W mutation, either alone or in combination
with kinase-dead RIPK2 substitutions, largely abolished the inhibi-
tory effect of ponatinib on RIPK2-induced NF-jB activation (Fig 2B)
and on NOD2 signaling as determined by RIPK2 ubiquitination, IjBa
degradation, phosphorylation of NF-jB (p65), and production of
2 of 16 The EMBO Journal 37: e99372 | 2018 ª 2018 The Authors
The EMBO Journal Mechanism of RIPK2 inhibitors Matous Hrdinka et al
Published online: July 19, 2018 
A B C
D E
F
G H
Figure 1. RIPK2 kinase activity is dispensable for NOD2 signaling.
A, B Intracellular flow cytometry analysis of CXCL8 in U2OS/NOD2 cells treated with L18-MDP (200 ng/ml, 4 h) and kinase inhibitors ponatinib (A) or GSK583 (B) as
indicated.
C Purification of Ub-conjugates using TUBE pulldowns from U2OS/NOD2 cells after treatment with L18-MDP (200 ng/ml, 1 h) and ponatinib or GSK583 as indicated.
Purified material and lysates were analyzed by immunoblotting, with actin as a loading control.
D Intracellular flow cytometry analysis of CXCL8 following L18-MDP treatment (200 ng/ml, 4 h) of parental U2OS/NOD2 cells and RIPK2 KO cells (clone C5-2)
reconstituted or not with RIPK2.
E Purification of Ub-conjugates from parental U2OS/NOD2 cells and RIPK2 KO cells (clone B7-1) reconstituted or not with RIPK2, treated with L18-MDP (200 ng/ml,
1 h). Purified material and lysates were analyzed by immunoblotting. Asterisk indicates a non-specific signal in the TUBE pulldown samples that co-migrates with
the signal for unmodified RIPK2.
F Schematic representation of RIPK2. Numbering below schematic refers to amino acid residues in human RIPK2 and indicate domain boundaries. K47 and D146 are
catalytic residues for ATP hydrolysis.
G Immunoblot analysis of U2OS/NOD2 RIPK2 KO cells (clone C5-2) reconstituted with RIPK2 variants or empty vector as indicated and stimulated (or not) with L18-
MDP (200 ng/ml, 1 h).
H Intracellular flow cytometry analysis of CXCL8 following L18-MDP treatment (200 ng/ml, 4 h) of cells described in (G).
Data information: Data in (A, B, D, H) represent the mean  SEM of 2–4 independent experiments, each performed in duplicate. Statistical significance in (A) and (B) is
determined in relation to L18-MDP-stimulated samples without inhibitor. **P < 0.01, n.s., not significant. Two-way ANOVA was used to determine statistical significance.
See also Fig EV1.
Source data are available online for this figure.
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Figure 2. Ponatinib antagonizes NOD2 signaling through binding to RIPK2 but independently of its kinase activity.
A Purification of Ub-conjugates from U2OS/NOD2 RIPK2 KO cells (clone C5-2) reconstituted with RIPK2 variants or vector as indicated and treated with L18-MDP
(200 ng/ml, 1 h) and/or ponatinib. Purified material and lysates were analyzed by immunoblotting. Asterisk indicates a non-specific signal in the TUBE pulldown
samples that co-migrates with the signal for unmodified RIPK2.
B NF-jB activity in lysates of HEK293FT cells transfected with dual luciferase NF-jB reporters and HA-RIPK2, and treated with DMSO or ponatinib (200 nM, 24 h) as
indicated. Relative luciferase activity in ponatinib-treated samples is shown relative to the activity in the corresponding HA-RIPK2 transfected sample not treated
with inhibitor.
C Structure of the RIPK2 kinase domain in complex with ponatinib (green) (PDB ID: 4C8B). Sticks are shown for catalytic residues Lys47 (blue) and Asp146 (red), and the
gatekeeper residue Thr95 (yellow).
D NanoBRET assay in HEK293 cells transiently transfected with the NanoLuc-RIPK2. Cells were treated with serial dilutions of SGC-590001 probe and incubated with
ponatinib (1 lM) or DMSO as a control for 3 h before measurement of BRET ratios. Gray box indicates range of ponatinib concentrations used in signaling
experiments in this study.
E Purification of Ub-conjugates from U2OS/NOD2 RIPK2 KO cells reconstituted with RIPK2 variants or vector as indicated and treated with L18-MDP (200 ng/ml, 1 h)
and/or ponatinib (100 nM). Purified material and lysates were analyzed by immunoblotting.
F Intracellular flow cytometry analysis of CXCL8 of U2OS/NOD2 RIPK2 KO cells reconstituted retrovirally with RIPK2 variants or vector as indicated and treated with
L18-MDP (200 ng/ml, 4 h) and ponatinib (50 nM). Values represent CXCL8-positive cells relative to L18-MDP treatment for each RIPK2 variant or empty vector.
Data information: Data in (B, D, F) represent the mean  SEM of 3–4 independent experiments, each performed in duplicate. **P < 0.01, n.s., not significant. Two-way
ANOVA was used to determine statistical significance. See also Appendix Fig S1.
Source data are available online for this figure.
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CXCL8 (Fig 2E and F). Together, these observations show that
ponatinib inhibits NOD2 signaling through its binding to RIPK2 but
not by inhibiting the kinase activity of RIPK2.
Development of a new series of potent small molecule
RIPK2 inhibitors
Ponatinib displays highly promiscuous inhibitory activity (Fauster
et al, 2015; Najjar et al, 2015), and clinical development of GSK583
was halted (Haile et al, 2016), raising a need for new classes of RIPK2
inhibitors. We have developed a new chemical series of RIPK2 inhibi-
tors, termed CSLP. A subset of these inhibitors, exemplified by
CSLP37 and CSLP43, displayed excellent potency in the NOD2/
HEKBlue reporter assay, measuring NF-jB activation in response to
L18-MDP [Table 1; full details of the synthesis and structure–activity
relationship (SAR) will be reported separately (CS, BD, DMP, ALD,
LL, MH, LS, MGH, MHU, ANB, AD, GDC, manuscript in prepara-
tion)]. However, correlation analysis of an entire panel of CSLP
analogs revealed a startling disparity between inhibition of RIPK2
kinase activity in vitro and suppression of the NOD2/RIPK2 pathway
in cells. Specifically, while many CSLP inhibitors displayed compara-
bly potent activity against RIPK2 kinase activity in vitro, only a small
subset of these compounds, i.e., CSLP37/43, provided potent
suppression of cellular NOD2/RIPK2-dependent responses as deter-
mined by L18-MDP-induced CXCL8 production in U2OS/NOD2 cells
and NF-jB activation in NOD2/HEKBlue cells (Figs 3A and B, and
EV2A; Table 1). Of note, CSLP37/43 and other CSLP inhibitors did
not have measurable toxicity in the cell lines used in this study
(Fig EV2B). Additionally, CSLP37 and CSLP43 showed no inhibitory
activity against the two closest mammalian homologs of RIPK2,
RIPK1, and RIPK3 (Fig EV2C).
To identify the reasons for the outstanding cellular activities
displayed by CSLP37/43, we focused on a small subset of highly
structurally similar CSLP analogs, differing in R1, R2, and R3 substi-
tuents, that displayed similar inhibition of RIPK2 in vitro but widely
variable cellular activity in the NOD2/HEKBlue reporter assay
(Table 1). We first examined whether these molecules displayed
major differences in binding to RIPK2 in cells by using the nano-
BRET RIPK2 target engagement assay described above (Fig 2D).
Indeed, while CSLP37/43 displayed a potent target engagement in-
line with their activities in the HEKBlue reporter assay, other CSLP
inhibitors, such as CSLP18, differing from CSLP37/43 only in the R1
group, CSLP38 (different R2), CSLP55 (different R3), CSLP48 (dif-
ferent R1 and R2), displayed lower target occupancy, correlating
with reduced cellular activities (Table 1). These data suggested that
the identity of the R1-R3 groups plays a major role in inhibitor bind-
ing to cellular RIPK2, which dictates the ability of CSLP inhibitors to
suppress NOD1/2 signaling. We also examined target residence time
by determining the time required for a nanoBRET probe to engage
RIPK2 after washout of the inhibitor from the cells (t1/2) to further
Table 1. In vitro and cellular activities of CSLP analogs.
Compound
ID X R1 R2 R3
IC50 (nM)
In vitro kinase Cellular activity
RIPK2 ADPGIo HEKBlue NOD2
nanoBRET RIPK2
binding
nanoBRET residence
time, min
CSLP43 NH2 OMe OMe -NHSO2
nPr 19.9  0.8 1.3  0.4 10.1  3.8 106.9
CSLP37 NH2 F OMe -NHSO2
nPr 16.3  4.6 26.3  3.7 36.3  20.2 27.1
CSLP18 NH2 H OMe -NHSO2
nPr 31.6  8.7 476.0  96.7 577.6  34.1 66.6
CSLP38 NH2 F H -NHSO2
nPr 39.1  1.5 740.3  60.7 166.8  19.0 106.5
CSLP48 NH2 H OH -NHSO2
nPr 53.5  5.7 > 5,000 1,231.3  344.5 126.7
CSLP53 Me F OMe -NHSO2
nPr 1,414.5  311.6 2,556.5  252.8 > 10,000 ND
CSLP55 NH2 F OMe OMe 39.1  3.9 595.1  69.6 194.6  47.1 6.8
WEHI-345 37.3  1.3 3,370.7  382.8 521.2  171.6 7.5
Compounds were tested against recombinant RIPK2 kinase using ADPGlo assay, L18-MDP-induced NF-jB reporter assay (HEKBlue assay), nanoBRET cellular
RIPK2 target engagement assay (in HEKBlue cells), and nanoBRET cellular RIPK2 residence time assay (in HEKBLue cells). ND—not determined due to very poor
binding of CSLP53 to RIPK2 in nanoBRET assay. For each inhibitor, at least three titrations were performed and data were used to calculate average IC50 and SD
values. Details of each assays are described in the Appendix Supplementary Methods. Chemical structure of the CSLP scaffold and WEHI-345 is shown in above
table.
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Figure 3. CSLP series of RIPK2 inhibitors reveal molecular determinants for NOD2 pathway inhibition.
A Comparison of inhibitory activity of CSLP compounds on in vitro RIPK2 kinase activity (ADPGlo)) and NOD2 signaling in cells (HEKBlue). Compounds characterized
further in this study are indicated in red.
B Intracellular flow cytometry analysis of CXCL8 in U2OS/NOD2 cells treated with L18-MDP (200 ng/ml, 4 h) and CSLP inhibitors as indicated. Data represent the mean
of three independent experiments.
C Chemical structure of CSLP compounds (18, 37, 43) that differ only in R1 group.
D Structure of RIPK2 kinase domain in complex with CSLP18 (orange) (PDB ID 6FU5). Sticks are shown for catalytic residues Lys47 and Asp146 (in DFG motif), Glu66
forming a salt bridge to Lys47 in active Glu-in conformation, and residues involved in binding of CSLP inhibitors as described in the text.
E Spacefill rendering of RIPK2 kinase domain structure with CSLP18 (top) and models with CSLP37 (bottom left) and CSLP43 (bottom right). Dark gray represents areas
occupied by RIPK2; white areas indicate empty spaces in CSLP binding pocket. Dotted white circle indicates cavity occupied by R1 group of CSLP37/43. Dotted black
box indicates region shown for models with CSLP37 and CSLP43.
F Molecular docking model of RIPK2 kinase domain in complex with CSLP43 (green) based on RIPK2/CSLP18 structure from (D). Key residues from CSLP18/RIPK2
structure and residues forming “R1” pocket, Ala45, Lys47, Ile93, Thr97 are shown as sticks.
G Comparison of the binding poses of CSLP43 (blue) docking model from (E) based on RIPK2/CSLP18 structure (C) with other RIPK2 kinase inhibitors—Compound 7f
(PDB ID 5W5O), ponatinib (PDB ID 4C8B), GSK583 (PDB ID 5J7B), and WEHI-345 (molecular docking model based on RIPK2/CSLP18 structure). While compound 7,
ponatinib, GSK583 occupy similar or larger spaces in the deep pocket, WEHI-345 does not contain groups equivalent to R1 and R3 of CSLP43.
H Intracellular flow cytometry analysis of CXCL8 of U2OS/NOD2 RIPK2 KO cells reconstituted with WT RIPK2 or T95W mutant, and treated with L18-MDP (200 ng/ml,
4 h) and CSLP inhibitors as indicated. Values represent CXCL8-positive cells relative to L18-MDP treatment for each RIPK2 variant without inhibitor treatment.
Data information: Data in (H) represent the mean  SEM of three independent experiments. *P < 0.05, **P < 0.01, n.s., not significant. Two-way ANOVA was used to
determine statistical significance. See also Fig EV2.
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elucidate whether the observed differences in potency may reflect
changes in off-rates of the inhibitors, but found no correlation
(Table 1, nanoBRET residence time). These data suggested that effi-
cient target engagement is a requisite for potent cellular activity of
CSLP molecules, which is dictated by the unique combination of
R1-R3 substituents.
To further understand the structural contributions of R1-R3, we
crystallized RIPK2 in complex with CSLP18 (Table 1), containing a
hydrogen (H) in the R1 position compared to fluorine (F) and
methoxy (OMe) in CSLP37 and 43, respectively (Fig 3C and D;
Table EV1). Overall, the complex with CSLP18 revealed RIPK2 in an
inactive conformation previously shown for Type I1/2A inhibitors
(Wu et al, 2015; Roskoski, 2016). Inhibitors in this class interact
exclusively within the ATP-binding pocket, in which a number of
critical residues are misplaced from their active positions. Specifi-
cally, when compared to structures of active RIPK2 in complex with
the ATP analog AMP-PNP, the RIPK2-CSLP18 structure showed mis-
orientation of the catalytic residues Asp146 of the HHD motif and
Asp164 of the DFG motif, a slight misalignment of the R-spine, a
shifted P-loop, and a completely disordered activation segment (AS)
which is partially structured in active RIPK2 (Fig EV2D). The struc-
ture is refined at 3.2 A˚ resolution, and the electron density map is of
sufficient quality in the region of the inhibitor to place the inhibitor
and its relevant functional groups with reasonably good precision
(Fig EV2E). CSLP18 forms two hydrogen bonds to the backbone of
the hinge segment residues Glu96 and Met98, and the R3 sulfon-
amide forms a hydrogen bond to Asn151. The R3 hydrogen bond
helps position the phenyl ring and R2 OMe group, which inserts into
a sub-pocket formed by the side chains of Glu66 and Leu70 of the
aC-helix (Fig 3D). The R2 group of CSLP18 fits the binding pocket
snugly. However, the R1 position does not optimally fill the
hydrophobic pocket (termed deep pocket) formed by the side chains
of Ala45, Lys47, Ile93, and gatekeeper Thr95 located on the b3 and
b5 strands of the b sheet bundle (Fig 3D and E). This is further
revealed by the molecular docking of CSLP37 (R1 = F) and CSLP43
(R1 = OMe), which demonstrates that the larger R1 groups of these
molecules more optimally fill the deep pocket (Figs 3E and F, and
EV2F). Notably, examining available crystal data, we observed that
all previously reported inhibitors that potently antagonize NOD2
signaling, including GSK583, ponatinib, and the recently reported
compound 7f (Canning et al, 2015; Nachbur et al, 2015; Najjar et al,
2015; Haile et al, 2016; He et al, 2017), all occupy the deep pocket
(Fig 3G).
Lastly, consistent with this binding mode and similar to our
ponatinib data (Fig 2F), inhibition of NOD2 signaling by CSLP37
and CSLP43 was no longer observed in cells expressing a mutant
RIPK2 with a bulky tryptophan (W) replacing T95 gatekeeper
residue forming part of the pocket occupied by the R1 group (Fig 3F
and H). In contrast, inhibition of signaling by CSLP48 and CSLP55,
which displayed poor engagement of cellular RIPK2, was not nega-
tively impacted by the T95W mutation (Fig EV2G).
CSLP37/43 selectively inhibit NOD responses in cells and display
potent activity in vivo
To further establish cellular activities of CSLP37 and CSLP43, we
first confirmed that these molecules efficiently blocked MDP-elicited
inflammatory signaling by measuring the release into the media of
TNF (tumor necrosis factor), which is stimulated in macrophages in
response to NOD2 activation (Ammann et al, 2014). CSLP37 and
CSLP43 blocked the release of TNF in these cells with similar IC50
values as determined in the NOD2/HEKBlue assay, while CSLP48
and CSLP55 displayed substantially lower inhibitory activities
(Figs 4A and B, and EV3A). In contrast, neither CSLP37 nor CSLP43
attenuated the TNF release following an unrelated pro-inflammatory
stimulation mediated through Toll-like receptor 4 (TLR4) activation
by LPS, even when used at 1 lM (Fig EV3B). Similarly, in experi-
ments with human THP1 monocytes containing an NF-jB-SEAP
reporter (THP1Blue), CSLP37 and CSLP43 selectively blocked NOD1
and NOD2 responses at low nanomolar concentrations, with no
detected effect on NF-jB responses following stimulation of cells
with the non-NOD agonists: TLR1 and TLR2 agonist Pam3CSK4,
LPS, or heat-killed Listeria monocytogenes (HKLM), which stimu-
lates mainly TLR2 (Fig 4C).
Nachbur et al (2015) described a promising ATP-competitive
RIPK2 inhibitor, WEHI-345, which displayed high affinity against
RIPK2 kinase in vitro but showed > 10-fold lower cellular potency
(Table 1; Fig 4A), and only partially inhibited the increase in
serum levels of TNF in mice challenged with MDP (Nachbur
et al, 2015). CSLP37 displayed improved cellular potency over
WEHI-345 (Table 1), and when compared side-by-side with
WEHI-345 in mice challenged with intraperitoneal injection of
MDP, pretreatment with CSLP37 potently reduced MDP-elicited
serum TNF levels, whereas WEHI-345 provided a partial reduc-
tion (Fig 4D). Overall, these data suggest that CSLP37 and
CSLP43 represent a new class of RIPK2 inhibitors, which display
comparably high cellular potency to ponatinib and GSK583,
strong selectivity toward cellular NOD1/2 responses, and effective
inhibitory activity in vivo.
Kinase inhibitors antagonize RIPK2-XIAP interaction to inhibit
NOD2 signaling
XIAP and cIAPs ubiquitinate RIPK2 following NOD2 stimulation
(Damgaard et al, 2012), and the interaction between the XIAP BIR2
domain and the RIPK2 kinase domain is needed for NOD2 signaling
(Damgaard et al, 2013; Chirieleison et al, 2017). Small molecule IAP
antagonists such as Compound A (CpA) can block NOD2 signaling
by interfering with the interaction between XIAP and RIPK2 and
thereby prevent the ubiquitination of RIPK2 by XIAP (Fig 5A; Krieg
et al, 2009; Damgaard et al, 2013; Hrdinka et al, 2016). Considering
that ponatinib efficiently blocked RIPK2 ubiquitination and that
WEHI-345 interferes with the IAP-RIPK2 interaction (Nachbur et al,
2015), we hypothesized that ponatinib may inhibit NOD2 signaling
by interfering with the XIAP-RIPK2 binding interface. In support of
this, pretreatment of cells with ponatinib prevented the co-immuno-
precipitation of endogenous RIPK2 with ectopically expressed HA-
tagged XIAP (Fig 5A). Furthermore, addition of ponatinib to cell
lysates interfered with the ability of recombinant GST-tagged XIAP
BIR2 domain (GST-BIR2-XIAP) bound to Glutathione Sepharose to
pull down RIPK2 (Figs 5B and EV4A). Strikingly, addition of
GSK583, CSLP37, or CSLP43 to cell lysates also efficiently antago-
nized pulldown of RIPK2 by GST-BIR2-XIAP. whereas CSLP48 and
CSLP55, which displayed lower potency in the cells due to the poor
occupancy of the deep pocket of RIPK2, had little effect (Fig 5C).
The region in the RIPK2 kinase domain (KD) responsible for binding
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to the XIAP BIR2 domain is not known, and the interaction may
therefore be either direct or indirect, involving another cellular
component. To test this, GST-BIR2-XIAP pulldown experiments
were performed with recombinant human RIPK2 kinase domain
(KD) instead of cell lysates. Under these conditions, GST-BIR2-XIAP
binding to RIPK2 was maintained and was still antagonized by
GSK583, CSLP37, and CSLP43, indicating that XIAP and RIPK2 inter-
act directly through the XIAP BIR2 domain and the RIPK2 KD
(Fig 5D). cIAP1 also interacts with RIPK2 via its BIR2 domain, and
the interaction can be antagonized by WEHI-345 (Nachbur et al,
2015). Akin to this, CSLP37 and CSLP43 both antagonized the
interaction between GST-BIR2-cIAP1 and RIPK2 in cell lysates
(Fig EV4B), suggesting that cIAP1 and XIAP interact with RIPK2
through a similar mechanism. In concordance with the observed
potency of CSLPs to interfere with the XIAP-RIPK2 interaction,
CSLP37 and CSLP43 inhibited RIPK2 ubiquitination in cells stimu-
lated with L18-MDP, while CSLP48 and CSLP55 again had little or
no effect (Fig 5E and EV4C and D). Taken together, these data
suggest that potent inhibition of NOD2 cellular responses by pona-
tinib, GSK583, CSLP37, and CSLP43 involves interference with the
RIPK2-IAP binding interface and therefore the critical step of RIPK2
ubiquitination by XIAP.
Mapping of XIAP/RIPK2 binding interface
Having determined that the BIR2 domain of XIAP interacts directly
with the RIPK2 kinase domain, we set out to map the region in
RIPK2 responsible for the interaction. For this, we analyzed by
SPOT assay the binding of recombinant GST-BIR2-XIAP to 15-mer
peptides derived from a walk-through of the entire RIPK2 coding
sequence with a frameshift of 3 amino acids (Fig EV5A; Dataset
EV2). Seven putative interacting peptides were identified in the
kinase domain of RIPK2 (Fig EV5A, blue squares; Fig EV5B). These
seven peptides were printed in triplicate on a new array and probed
with either GST-tagged WT XIAP BIR2 domain or a BIR2 domain
containing a mutation in the IAP-binding motif groove (D214S) that
interferes with RIPK2 binding (Figs 6A and EV4A, Dataset EV3;
Damgaard et al, 2013). This showed that the WT BIR2 domain binds
predominantly to two RIPK2 peptides, A13 (residues 28-42), and E6
(residues 163–177; Fig 6A and B). Comparison of the binding of WT
versus D214S BIR2 domain showed that only the interaction with
peptide A13 (position B1, D1, and F1) was reduced when probed
with the D214S mutant (Fig 6A and B). This region spans b2 and
the following b2-b3 loop of the N-lobe of the RIPK2 kinase domain
(Fig 6C and D). Strikingly, single-residue Ala- and Leu-scanning
A C
B D
Figure 4. Cellular and in vivo characterization of novel RIPK2 inhibitors on inflammatory signaling.
A, B ELISA measurement of TNF release from RAW264.7 cells treated with MDP (10 lg/ml, 24 h) and CSLP compounds or RIPK2 inhibitor WEHI-345 as indicated. Values
are expressed relative to the TNF release in cells treated with MDP without inhibitor (A) and are used for calculation of IC50 values (B).
C Inhibition of NF-jB reporter activity by CSLP37 (top) and CSLP43 (bottom) in THP1Blue cells treated with PRR ligands: MDP (10 lg/ml); TriDAP (10 lg/ml); E. coli
LPS (10 ng/ml); HKLM (1 × 107 cells/ml; or Pam3CSK4 (10 ng/ml). Inhibition values are used for calculating IC50 of MDP and TriDAP responses as shown.
D Inhibition of MDP-elicited TNF release by CSLP37 in vivo. Mice (n = 6 per group) were administered i.p. with 10 mg/kg of WEHI-345 or CSLP36 30 min prior to the
i.p. injections of 100 lg/mouse of MDP. After 4 h, blood was collected by cardiac puncture and circulating levels of TNF were analyzed by ELISA.
Data information: Data represent the mean  SEM of three independent experiments. **P < 0.01, n.s., not significant. Two-tailed unpaired Student’s t-test was used to
determine statistical significance. See also Fig EV3.
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Figure 5. RIPK2 inhibitors antagonize NOD2 signaling by interfering with the XIAP-RIPK2 interaction.
A Co-immunoprecipitation and Western blot analysis of HA-XIAP (F495A; Ub ligase-dead) and endogenous RIPK2 from HEK293FT cells treated with IAP antagonist
compound A (CpA, 10 lM) or ponatinib (200 nM).
B Pulldown of RIPK2 from U2OS/NOD2 cell lysates with recombinant GST-tagged BIR2 domain (residues aa 124–242) from XIAP (GST-BIR2-XIAP) in the presence of
ponatinib or GSK583 as indicated. Purified material and lysates were analyzed by immunoblotting.
C Pulldown of RIPK2 from U2OS/NOD2 cell lysates with recombinant GST-BIR2-XIAP in the presence of CSLP inhibitors. Inhibitors were used at 100-fold IC50 of RIPK2
kinase activity: ponatinib (10 lM), GSK583 (5 lM), CSLP37 (1.8 lM), 43 (2 lM), 48 (5.7 lM), and 55 (3.9 lM) as indicated. Purified material and lysates were analyzed
by immunoblotting.
D Pulldown of recombinant RIPK2 kinase domain (dephosphorylated) with recombinant GST-BIR2-XIAP in the presence of CSLP inhibitors as indicated. Inhibitors were
used at the same concentrations as in (C). Purified material and lysates were analyzed by immunoblotting.
E Purification of Ub-conjugates from THP-1 cells after treatment with L18-MDP (200 ng/ml, 1 h) and CSLP inhibitors as indicated. Purified material and lysates were
analyzed by immunoblotting.
Data information: Asterisk in (B–D) indicates a cleavage product of GST-BIR-XIAP recognized by the GST antibody. See also Fig EV4.
Source data are available online for this figure.
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analysis of the A13 peptide and an overlapping peptide covering the
b2-b3 loop and b3 (residues 37-51) revealed that mutation of R36,
H37, or R41 impaired BIR2 binding (Figs 6E and EV5C, Dataset
EV4). To investigate the function of the R36/R41 patch, we reconsti-
tuted U2OS/NOD2 RIPK2 KO cells with RIPK2 mutants in which
R36 and/or R41 were substituted with leucine (Fig EV5D). Mutation
of these residues impaired the interaction with GST-BIR2-XIAP in
pulldown experiments with lysates from the reconstituted cells
(Fig 6F). Accordingly, the RIPK2 R41L single and R36L/R41L double
mutants failed to fully restore NOD2 signaling in the reconstituted
cells (Fig 6G). Intriguingly, R36 and R41 are surface-exposed and
form a basic patch positioned on top of the deep pocket occupied by
the compounds that potently inhibit NOD2 signaling (Figs 6H and
EV5E), implying that the compounds alter the ability of XIAP to
interact with the R36/R41 patch (Fig 6D).
Discussion
Targeting NOD1 and NOD2 signaling with RIPK2 inhibitors is an
attractive strategy for the treatment of chronic inflammatory condi-
tions associated with deregulated NOD signaling. These conditions
include hereditary auto-inflammatory syndromes associated with
activating mutations in NOD2, such as early-onset sarcoidosis and
Blau syndrome, and early-onset inflammatory bowel disease, in
particular Crohn’s disease where NOD2 signaling may play an
important role (Kanazawa et al, 2005; Stronati et al, 2008; Negroni
et al, 2009; Yao et al, 2011; Caruso et al, 2014; Uhlig & Schwerd,
2016). XIAP-mediated ubiquitination of RIPK2 emerged as a requi-
site step in pro-inflammatory signaling downstream of NOD1 and
NOD2 (Bauler et al, 2008; Damgaard et al, 2012), and XIAP-selec-
tive IAP antagonists have been recently reported to efficiently
impair NOD signaling (Goncharov et al, 2018). However, continu-
ous inhibition of XIAP as a therapeutic strategy raises concerns
due to the role of this protein in innate immune and cell death
regulation and because the loss-of-function mutations of XIAP
associate with hereditary very early-onset (VEO) IBD and X-linked
lymphoproliferative disease type 2 (XLP-2) (Rigaud et al, 2006;
Damgaard et al, 2013; Speckmann et al, 2013; Latour & Aguilar,
2015).
Initial notions that RIPK2 kinase activity facilitates NOD1 and
NOD2 signaling were in part based on the finding that kinase activ-
ity may be required for RIPK2 stability in cells, and in part, on the
fact that kinase inhibitors could inhibit productive NOD1 and NOD2
signaling (Windheim et al, 2007; Nembrini et al, 2009; Tigno-
Aranjuez et al, 2010). However, while several promiscuous clinical
Type II inhibitors, such as ponatinib, regorafenib, and sorafenib
(Canning et al, 2015) displayed very potent (low nanomolar) cellu-
lar activity against NOD1- and NOD2-mediated responses, a number
of Type I ATP-competitive inhibitors, such as gefitinib and WEHI-
345, showed reduced potency in cellular assays despite being
comparably potent to Type II molecules in inhibiting RIPK2 activity
in vitro (Tigno-Aranjuez et al, 2010; Canning et al, 2015; Nachbur
et al, 2015). In light of these discrepancies, in the present work we
sought to define the features of inhibitors necessary for cellular
potency against NOD responses.
We started by evaluating the role of RIPK2 catalytic activity in
NOD2 signaling. Strikingly, using reconstitution with two different
kinase-dead mutants of RIPK2 we discovered that RIPK2 kinase
activity is dispensable for NOD2 inflammatory signaling. Further-
more, ponatinib was still able to completely prevent these responses
even in the cells lacking catalytic activity of RIPK2, clearly indicat-
ing that efficient inhibition of NOD2 responses is not related to the
ability of the inhibitors to block the catalytic activity of RIPK2.
Notably, Goncharov et al (2018) recently undertook similar experi-
ments and reached the same conclusion that catalytic activity of
RIPK2 is not required for NOD2 responses.
As an alternative, we explored whether selected inhibitors may
interfere with RIPK2 ubiquitination by XIAP, which is indispensable
for NOD1 and NOD2 signaling (Krieg et al, 2009; Damgaard et al,
2012, 2013). Indeed, we show that all potent NOD pathway inhibi-
tors, including ponatinib, GSK583, and the newly developed CSLP37
and CSLP43 efficiently abrogate both XIAP binding to RIPK2 and
RIPK2 ubiquitination. Furthermore, using a panel of closely related
▸Figure 6. Mapping and functional characterization of XIAP-binding site on RIPK2.A, B SPOT peptide array of seven putative interacting peptides of the RIPK2 kinase domain, identified in Fig EV5A, probed with purified GST-XIAP-BIR2 (WT or D214S;
RIPK2 interaction-defective mutant), and visualized by anti-His-HRP (A). The peptides were spotted and analyzed in triplicates (blue boxes). 11xHis was spotted in
triplicate as a positive control for anti-His-HRP staining (yellow boxes). Table (right) indicates the position of each peptide on the membrane and the amino acids
in human RIPK2 covered by each peptide. Heat map presentation of each spot in the peptide array quantified using ImageJ (B). Values represent the relative
intensity of the mean of each peptide triplicate to the mean of the positive control triplicate in the peptide array.
C Primary sequence alignment of the N-terminal region in RIPK2, including the region represented in A13 peptide. Alignment shows high evolutionary conservation of
the region. Residues R36 and R41 studied for XIAP binding are shown in blue.
D Cartoon representation of the structure of RIPK2 kinase domain (PDB ID: 5AR2). Region represented in A13 peptide is shown in blue. Sticks are shown for R36 and
R41 to highlight their surface orientation. RIPK2 inhibitor GSK583 (yellow) is modeled into structure based on PDB ID: 5J7B (Haile et al, 2016).
E SPOT peptide array of the A13 peptide in which each residue is substituted with alanine (Ala-scan) or leucine (Leu-scan) was probed for binding of GST-XIAP-BIR2.
Each peptide is spotted in triplicate indicated by #1-#3. Yellow boxes indicate the residues in A13 where binding is reduced by modification. The bound BIR2
domain was visualized by anti-His-HRP.
F Pulldown of RIPK2 variants from U2OS/NOD2 cell lysates with recombinant GST-BIR2-XIAP. Purified material and lysates were analyzed by immunoblotting.
G Intracellular flow cytometry analysis of CXCL8 in U2OS/NOD2 RIPK2 KO cells reconstituted with RIPK2 variants following stimulation (or not) with L18-MDP
(200 ng/ml, 4 h). Values represent fraction of CXCL8-positive cells. Data represent the mean  SEM of five independent experiments.
H Structure of XIAP-BIR2 (PDB ID: 1C9Q) and RIPK2 kinase domain (KD) (PDB ID: 5AR2). RIPK2 inhibitor GSK583 (yellow) is modeled into the structure based on (PDB ID:
5J7B) (Haile et al, 2016). Surface charge representation shows an acidic patch around residues E211, D214, and E219 in XIAP and a basic patch generated by R36
and R41 in RIPK2 (black dotted circles). IAP-binding motif (IBM) groove is indicated by green dotted line in cartoon representation. The inhibitor-binding pocket is
indicated by red dotted line.
Data information: **P < 0.01, n.s., not significant. Two-way ANOVA was used to determine statistical significance. See also Fig EV5.
Source data are available online for this figure.
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CSLP analogs, we show that inhibition of RIPK2 ubiquitination does
not generally reflect the affinity of these molecules toward the
RIPK2 kinase domain in vitro.
This leaves open a critical question of what defines the ability of
some, but not all RIPK2 inhibitors to block cellular signaling by
interfering with binding of the XIAP BIR2 domain to RIPK2. The
crystal structure of one of the CSLP analogs, CSLP18, with RIPK2
provided key insights into this. The RIPK2-CSLP18 complex
structure revealed the inhibitor occupying the ATP pocket of RIPK2
with the R1-R3 groups of the inhibitor inserted into the deep pocket
behind the adenine-binding site. Structure–activity relationship anal-
ysis of a subset of closely related CSLP analogs revealed that the R1-
R3 groups dictate high cellular activity of CSLP analogs (Fig 3F).
Molecular docking analysis showed that two methoxy groups in the
R1 and R2 positions provide an optimal fit in the deep pocket of
RIPK2, leading to low nanomolar cellular activity of CSLP43.
A B
D
C
E
F
G
H
Figure 6.
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Consistently, molecules lacking R1 or R2, or possessing smaller
(CSLP37, 18, 38, 48; Table 1) or slightly larger (such as R1 = Cl or
R2 = OEt, data not shown, CS, BD, DMP, ALD, LL, MH, LS, MGH,
MHU, ANB, AD, GDC, manuscript in preparation) R1/R2 groups
display greatly reduced cellular activity. Additionally, molecules
lacking the hydrogen bond acceptor sulfonamide in R3 (CSLP55;
Table 1) also loose cellular activity. The binding of CSLP analogs to
RIPK2 in intact HEKBlue cells, measured by nanoBRET assay,
closely correlated with the functional activity of the inhibitors in
blocking NOD2 signaling. In sum, these data suggested that occu-
pancy of the deep pocket is essential for the ability of CSLP analogs
to bind endogenous RIPK2 and to block signaling by interfering with
XIAP binding. This “cellular-specific” role of the deep pocket of
RIPK2 contrasts with the more conventional changes that affect
affinity of the inhibitors toward RIPK2, such as the absence of the
hinge-interacting amino group in CSLP53, leading to the loss of both
in vitro and cellular activities.
This mode of activity may also be relevant for other inhibitors
since an alignment of published RIPK2 structures indicates that all
potent inhibitors of NOD signaling such as ponatinib (Canning et al,
2015) and GSK583 (Haile et al, 2016) extend into the deep pocket
occupied by R1-R3 substituents of the CSLP series (Fig 3G). Another
recently described ATP-competitive RIPK2 inhibitor series with potent
activity in cells (e.g., compound 7f) possesses a phenyl ring similar to
the CSLP inhibitors (He et al, 2017). While this molecule lacks a group
corresponding to the R2 group in the CSLP series, it contains a pyri-
dine and the crystal structure indicates the presence of a water mole-
cule in place of R2 in this case (Fig 3G). Conversely, the previously
reported Type I inhibitor WEHI-345 likely does not fully occupy the
deep pocket as it lacks both R1 and R3 (Fig 3G), which possibly
explains its reduced cellular activity (Nachbur et al, 2015). Overall,
these results reveal that while it is possible to inhibit NOD responses
using molecules targeting the ATP-binding pocket, engaging the deep
pocket of RIPK2 is critical for the potency of the molecules.
In a complementary set of data, we reveal the molecular interface
between RIPK2 and XIAP. Binding data and functional assays
suggest that the basic patch formed by R36/R41 located in the N-
terminal loop connecting b2 and b3 mediates XIAP binding via a
direct, electrostatic interaction with the acidic patch formed by E211,
D214, E219 in the BIR2 IBM groove (Fig 6I). This discovery has
multiple significant implications. First, it explains why SMAC and
some IAP antagonists disrupt the XIAP-RIPK2 interaction and inhibit
NOD2 signaling since these molecules dock into the pocket in the
IBM groove and thereby occlude the acidic patch (Krieg et al, 2009;
Damgaard et al, 2013; Figs 6H and EV5F). It also explains why
charge-changing mutation of the key IBM groove residues D214
(D214S) and E219 (E219R) interfere with RIPK2 binding, and, possi-
bly, why mutation of the basic H223 residue to a hydrophobic
residue (H223V) enhances RIPK2 binding (Damgaard et al, 2013).
Second, identification of the RIPK2/XIAP binding interface offers an
opportunity for developing new generations of inhibitors that may
possess selectivity toward this interaction as opposed to general inhi-
bition of XIAP functions, some of which may be critical. Third, it
raises the question whether the deep pocket of RIPK2 (formed by b3/
b5) may possess additional importance because it is located in close
proximity and on the opposite side of b3 from the XIAP binding site
(Fig 6H). One can easily envision that if XIAP binding is associated
with movement of b3, molecules occluding the deep pocket in an
allosteric fashion could interfere with the binding. Contrary to this,
RIPK2’s ability to mediate NOD2 signaling does not appear to be
sensitive to conformational changes elsewhere in the ATP-binding
pocket. Pellegrini et al (2017) recently demonstrated significant
conformational changes in the ATP-binding pocket associated with
the inactivating mutations D146N and K47R and, yet, we find that
both mutants retain the ability to be ubiquitinated by XIAP and medi-
ate signaling in response to NOD2 stimulation. In accordance with
this, structural comparison of the RIPK2 R36/R41 XIAP-binding area
indicates there are no significant changes in the conformation
between WT RIPK2 and the mutant proteins (Fig EV5E).
IAP family members have emerged as important mediators of
innate immune receptor responses by ubiquitinating RIPKs within
signaling complexes. RIPK2 binds to and is ubiquitinated by both
XIAP and cIAP1, but only the interaction with XIAP is required for
NOD1 and NOD2 inflammatory signaling, whereas cIAPs are
dispensable (Damgaard et al, 2013; Stafford et al, 2018). Nonethe-
less, recent work suggests that TNF-induced ubiquitination of RIPK1
by cIAPs acts in concert with XIAP-mediated RIPK2 ubiquitination
in vivo to provide a full innate immune response to bacterial pepti-
doglycans (Stafford et al, 2018). Interestingly, small molecule RIPK2
inhibitors interfere with cIAP1-binding comparably to XIAP,
suggesting that these ubiquitin ligases likely share the binding inter-
face on RIPK2. It is therefore plausible that cIAPs contribute to as
yet to be defined RIPK2-mediated processes. Other innate immune
kinases, such as IRAK1 (Interleukin-1 (IL-1) receptor-associated
kinase 1) and IRAK4, are ubiquitination targets for other Ub ligases
such as TRAF6 and Pellino1 in TLR/IL-1R signaling (Cohen & Strick-
son, 2017). Remarkably, knowledge about the substrates of RIPK
and IRAK kinases is limited and there is a continuing debate about
the role of these proteins as true kinases versus their scaffolding
function, including as scaffolds for ubiquitination (Kawagoe et al,
2007; Kim et al, 2007; Koziczak-Holbro et al, 2008; Ordureau et al,
2008; Song et al, 2009; Vollmer et al, 2017; Wang et al, 2017; Anni-
baldi & Meier, 2018; Dziedzic et al, 2018). Our findings for RIPK2
exemplify the cross-talk between the kinase domain serving as a
binding interface for a Ub ligase (XIAP) and kinase inhibitors acting
as blockers of this interaction. This resolves a paradox of how ATP-
competitive inhibitors of kinase activity may serve to block a scaf-
folding catalysis-independent function of the protein. This example
may be applicable to other kinases, including other innate immune
kinases, whose role in signaling remains enigmatic.
Materials and Methods
Please see Appendix Supplementary Methods for further details on
all methods.
Generation of knockout and reconstituted cell lines
U2OS/NOD2 RIPK2 KO cells were generated using CRISPR/Cas9 KO
plasmids (containing gRNA, Cas9, and EGFP reporter; Santa Cruz
Biotechnology) as described in Elliott et al (2016). Reconstitution
with RIPK2 variants was performed by retroviral transduction using
pBABE-Puro plasmids and the retroviral packaging cell line
Phoenix-A. Cells were selected with 1 lg/ml puromycin (Invivo-
Gen) for 1 week.
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hNOD2-HEKBlue and THP1Blue assays
For HEKBlue assay, cells were seeded into clear 96-well plates at
7.5 × 103 cells/well and allowed to attach for 48 h. On the day of
the experiment, media was changed to 100 ll of HEKBlue detection
media (InvivoGen). Inhibitors were diluted and added in 0.5 ll
DMSO 15 min prior to the addition of 1 ng/ml L18-MDP (Invi-
voGen). After 8–9 h, absorbance at 620 nm was measured using
Victor3V plate reader (Perkin Elmer, Waltham, MA). Values of
media-only wells were subtracted and %inhibition for each
compound concentration relative to the DMSO/L18-MDP-treated
controls was calculated. Inhibition values  SD were fitted by non-
linear regression using Prism software (GraphPad Software, La
Jolla, CA) to calculate IC50 values. For THP1Blue assay, 1 × 10
5
cells were seeded in 200 ll of RPMI media in 96-well plates and
treated with inhibitors in 0.5 ll DMSO for 15 min prior to the addi-
tion of 10 lg/ml MDP, 10 ng/ml Pam3CSK4, 10 ng/ml E. coli LPS,
or 1 × 107 cells/ml heat-killed L. monocytogenes (InvivoGen) for
24 h. After induction, 20 ll of media was mixed with 180 ll of
QUANTI-Blue reagent (InvivoGen) and incubated at 37°C for 3–4 h,
followed by absorbance measurement at 620 nm. IC50 values were
calculated as described for HEKBlue assay.
Inhibition of MDP-elicited TNF release in vivo
Female 6- to 8-week-old C57Bl6/J mice (Jackson labs) were admin-
istered with the compounds i.p. 30 min prior to the i.p. injections of
MDP as previously described (Nachbur et al, 2015). After 4 h, blood
was collected by cardiac puncture. 100 ll of serum (diluted twofold)
per animal was analyzed using anti-mouse TNF ELISA (Thermo-
Fisher Scientific).
Recombinant protein expression and purification and ADPGlo
kinase assays
The BIR2 domains of XIAP and cIAP1 were cloned into the pGEX-
6P1 vector and were expressed in E. coli (BL21) cells as a fusion
protein with N-terminal 6xHis (XIAP BIR2 only) and GST tags.
Protein expression was induced with IPTG, and cells were lysed
using BugBuster protein extraction reagent (#70921, Merck Milli-
pore) according to manufacturer’s instructions. Proteins were puri-
fied with the FPLC protein purification system A¨KTA PrimePlus (GE
Healthcare Life Sciences) using HisTrap FF column purification
followed by gel filtration (HiLoad 26/600 Superdex 75 pg (GE
Healthcare Life Sciences)). Collected fractions were stored at 80°C
and used for probing of peptide array membranes. Expression and
purification of recombinant RIPK1-3 was performed as previously
described (Canning et al, 2015; Najjar et al, 2015). RIPK1-3 ADPGlo
kinase assays using 20 ng/well protein were performed for 2 h at
room temperature also as previously described (Canning et al, 2015;
Najjar et al, 2015).
Immunoprecipitation, pulldowns, and purification of endogenous
ubiquitin conjugates
For co-immunoprecipitation of HA-XIAP with RIPK2, transfected
and treated cells were lysed in TBS buffer containing 0.5% NP-40,
cOmplete and PhosSTOP inhibitors (Roche) and the lysate was
cleared by centrifugation. The lysates were incubated with anti-HA-
agarose overnight, washed 3× with lysis buffer, and analyzed by
immunoblotting. For GST pulldown experiments, U2OS/NOD2 cells
were lysed in TBS lysis buffer containing 0.5% NP-40, cOmplete
and PhosSTOP inhibitors (Roche). Cleared lysates were pretreated
with kinase inhibitors or DMSO and incubated with GST-XIAP-BIR2
bound to Glutathione Sepharose at 4°C overnight. Bound material
was washed 3× with lysis buffer or PBS, eluted with 15 mM
Glutathione in PBS, and analyzed by immunoblotting. In pulldown
experiments with recombinant (dephosphorylated) RIPK2 kinase
domain (Canning et al, 2015), inhibitors or DMSO control in PBS
were added together with RIPK2 kinase domain to GST-XIAP-BIR2
bound to Glutathione Sepharose. The bound material was eluted
and analyzed as described above. Ubiquitin conjugates were puri-
fied from treated cells using GST-1xUBAubq ubiquitin affinity reagent
(termed TUBE pulldown) and analyzed by immunoblotting as
described (Fiil et al, 2013).
Crystallization and structure determination
Crystals were grown using the vapor-diffusion in sitting drops. The
RIPK2:CSLP18 structure was determined as previously described
(Canning et al, 2015).
SPOT peptide assays
Cellulose-bound peptide arrays were prepared employing standard
Fmoc solid-phase peptide synthesis using a MultiPep-RSi-Spotter
(INTAVIS, Ko¨ln, Germany) as previously described (Picaud &
Filippakopoulos, 2015). The assay was performed using recombi-
nant 6xHIS-GST-BIR2 domain of XIAP protein, and bound protein
was detected using anti-His antibody HRP-conjugated. Intensity
quantification of SPOTs was performed using ImageJ software
(Schneider et al, 2012).
Dual luciferase reporter assay
Cells were co-transfected the NF-jB luciferase reporter construct
pBIIX-luc and a thymidine kinase-renilla luciferase construct. Addi-
tional plasmids were transfected where indicated and assay
performed as described in Damgaard et al (2012).
RIPK2 nanoBRET assay
HEK293 cells were transiently transfected with the NanoLuc-RIPK2
WT and T95W mutant RIPK2 constructs, plated into white 384-well
assay plates (Corning, Corning, NY), treated with serial dilutions of
SGC-590001, and incubated with 1 lM ponatinib or DMSO control
for 3 h. After addition of Nano-Glo Substrate (Promega) and Extra-
cellular NanoLuc Inhibitor (Promega), BRET ratios (450 nm and
610 nm) were determined using a PHERAstar FSX plate reader
(BMG Labtech). The preparation of SGC-590001 is described previ-
ously (Vasta et al, 2018). For nanoBRET experiments in HEKBlue
cells, cells were transfected with NanoLuc-RIPK2 WT and stimu-
lated with 1 ng/ml L18-MDP for 1 h prior to the inhibitor addition.
Cell density was adjusted to 2 × 105 cells/ml, and cells were incu-
bated with commercial nanoBRET tracer 6 (Promega) and various
inhibitor concentrations for 2 h at 37°C. After that, NanoLuc
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substrate mix (Promega) was added and BRET ratios were deter-
mined using a Victor3V plate reader (PerkinElmer, Waltham, MA).
Residence time measurements were performed similarly, except
cells were first incubated with the inhibitors, washed carefully to
remove un-bound inhibitor, and then incubated with nanoBRET
tracer and NanoLuc substrate. Emission signals were measured 60
times at 2-min intervals.
Docking experiments and modeling
Ligand docking of CSLP37 and CSLP43 was performed using Auto-
Dock molecular docking software (version 4.2.6) (http://autodock.
scripps.edu/) with a standard protocol. The co-crystal structure of
CSLP18 bound to RIPK2 was used for the docking experiment where
CSLP18 was extracted from the RIPK2 using Discovery Studio 2016
Client software (http://accelrys.com/). CSLP37 and CSLP43 ligands
were created and subjected to energy minimization using MM2 force
field. Grid maps were selected based on CSLP18-RIPK2 co-crystal
structure, and docking experiments were performed. The final pose
was selected based on the lowest binding energy and analyzed using
the PyMOL Molecular Graphics System, Version 2.0 Schro¨dinger,
LLC (https://pymol.org/2/). Molecular surfaces were generated by
mapping electrostatic charge on the models of RIPK2 (PDB: 5AR2)
and XIAP (XIAP, PDB:1CQ9) using APBS (Jurrus et al, 2018) as
implemented in PyMOL and are contoured between 10 and +10
kT/e as indicated in the figures.
Data availability
The accession number for the coordinates and structure factors for
the RIPK2 kinase domain bound by CSLP18 is PDB: 6FU5. The mass
spectrometry proteomics data have been deposited to the Proteo-
meXchange Consortium (http://proteomecentral.proteomexchange.
org) via the PRIDE partner repository (Vizcaino et al, 2013) with the
dataset identifier PXD009724.
Statistical analysis
Statistical analysis and calculation of IC50 values were performed
using Prism 6 (GraphPad Software). Unpaired Student’s t-test and
two-way ANOVA were used to determine statistical significance as
appropriate.
Expanded View for this article is available online.
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